Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 46 peer-reviewed journal articles Updated
Dermatology

Your First Steps with Acrodermatitis Continua of Hallopeau

At a Glance

Acrodermatitis continua of Hallopeau (ACH) is a rare, non-contagious variant of pustular psoriasis causing sterile blisters on fingers and toes. While stubborn, modern biologic therapies offer effective treatment. Without care, ACH can lead to permanent nail deformity and bone loss in the digits.

Receiving a diagnosis of Acrodermatitis continua of Hallopeau (ACH) often marks the end of a long search for answers and the beginning of a new journey toward management [1]. It is completely normal to feel overwhelmed, as this condition is exceptionally rare and its appearance can be distressing [2]. Because most doctors may only see one or two cases in their entire career, you are now entering a specialized area of dermatology [3][4].

Understanding Your Diagnosis

Acrodermatitis continua of Hallopeau is a rare, chronic variant of pustular psoriasis [4]. Unlike more common forms of psoriasis that cause scaly patches, ACH causes small, sterile pustules (blisters filled with white blood cells, not infection) that typically begin at the very tips of the fingers or toes [1][5]. To understand what causes these blisters and how they are identified, read our guide on The Biology and Diagnosis of ACH.

The condition is considered recalcitrant, meaning it can be stubborn and resistant to standard treatments, often requiring a more specialized approach to achieve relief [6][7].

Three Stabilizing Facts

When you are in a “panic spiral,” it helps to anchor yourself in what we know for certain:

  1. It is not an infection. Although the pustules may look like an infection (such as a staph infection or “whitlow”), they are sterile [1][8]. You cannot spread ACH to other people, and you cannot “catch” it from yourself on other parts of your body through contact.
  2. Modern treatments are evolving rapidly. While older treatments were often limited, new biologic therapies—specifically those targeting the IL-17 and IL-36 pathways—have shown significant success in clearing even “stubborn” cases that did not respond to traditional creams [9][10][11]. You can learn more about these in our section on Treatment Strategy and Management for ACH.
  3. You are not alone in the “rare” community. While the exact number of people with ACH is so low that broad statistics are hard to find, the medical community now classifies it within the pustular psoriasis spectrum [4]. This means you benefit from the massive amount of research currently being done on Generalized Pustular Psoriasis (GPP) [12][13].

What Science Knows (and What is Still Being Discovered)

Research has made major leaps in the last decade, but some questions remain.

What Research Agrees On What is Still Uncertain
Genetic Drivers: Mutations in the IL36RN gene (which helps regulate inflammation) are a known cause in many patients [12][14]. Exact Prevalence: Because ACH is so rare, there is no “official” count of exactly how many people have it worldwide [3].
Physical Impact: If left untreated, the chronic inflammation can lead to onychodystrophy (nail loss or deformity) and osteolysis (softening or loss of the bone at the tip of the finger) [9][15]. Triggers: Why the condition starts in one specific finger or toe—and what triggers a “flare”—is still a subject of active study [16].
Systemic Risk: ACH is usually localized to the digits, but it can occasionally progress to or coexist with a more widespread form called Generalized Pustular Psoriasis [17][18]. Long-term Predictors: Doctors cannot yet predict with 100% certainty which patients will stay localized and which might experience a wider flare [19].

Navigating the Emotional Impact

The visible nature of ACH on the hands and feet can lead to significant psychological distress and “skin-focused” anxiety [2]. You may feel a sense of isolation because your local doctor might seem unfamiliar with the condition [3]. Seeking approach-oriented coping strategies—such as joining a rare disease community or working with a dermatologist who specializes in pustular diseases—is proven to reduce distress and improve quality of life [20][21]. Solid knowledge and a clear management plan are your best tools against the “panic spiral” [22]. Be sure to check our resources on Long-term Monitoring and Quality of Life with ACH.

In this guide

3 chapters

01

The Biology and Diagnosis of ACH

Learn about Acrodermatitis continua of Hallopeau (ACH) biology and diagnosis. Understand symptoms like sterile pustules, nail changes, and essential tests.

02

Treatment Strategy and Management for ACH

Explore treatment options for Acrodermatitis continua of Hallopeau (ACH). Learn about the treatment ladder, from topical creams to advanced biologic therapies.

03

Long-term Monitoring and Quality of Life with ACH

Learn how to manage Acrodermatitis continua of Hallopeau (ACH) long-term. Discover tips for wound care, monitoring bone loss, and improving quality of life.

Common questions in this guide

Is Acrodermatitis continua of Hallopeau contagious?
No, ACH is not an infection and it is not contagious. Although the blisters look like an infection, they are filled with sterile white blood cells and cannot be spread to others or to other parts of your body.
What causes Acrodermatitis continua of Hallopeau?
The exact cause is still being researched, but it is strongly linked to genetics. Mutations in the IL36RN gene, which helps regulate the body's inflammation, are a known driver in many patients.
What happens if Acrodermatitis continua of Hallopeau is left untreated?
Without proper treatment, the chronic inflammation from ACH can lead to onychodystrophy, which is permanent nail loss or deformity. It can also cause osteolysis, meaning the softening or loss of the bone at the tips of affected fingers or toes.
What are the newest treatments for ACH?
Modern treatments include new biologic therapies that specifically target inflammatory pathways like IL-17 and IL-36. These advanced medications have shown significant success in clearing stubborn cases that do not respond to traditional creams.
Can Acrodermatitis continua of Hallopeau spread to the rest of the body?
While ACH typically remains localized to the fingers and toes, it can occasionally progress to a more widespread condition known as Generalized Pustular Psoriasis. Your dermatologist will monitor you closely for any symptoms indicating the condition is spreading.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are you familiar with the most recent guidelines for treating ACH, or should I see a specialist in rare pustular psoriasis?
  2. 2.Has my diagnosis been confirmed through a skin biopsy or genetic testing for IL36RN mutations?
  3. 3.What specific symptoms should I watch for that might indicate the condition is becoming more generalized?
  4. 4.How will we measure the success of my treatment—is the goal total clearance, or stabilization?
  5. 5.What are the long-term risks to my nails and bones, and how can we prevent them?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Acrodermatitis continua of Hallopeau successfully treated with ixekizumab: A case report.

    Battista T, Guerrasio G, De Fata Salvatores G, et al.

    Dermatologic therapy 2022; (35(5)):e15383 doi:10.1111/dth.15383.

    PMID: 35174591
  2. 2

    Pustular psoriasis in Malaysia: A review of the Malaysian Psoriasis Registry 2007-2018.

    Teoh XY, Suganthy R, Voo SYM, et al.

    Experimental dermatology 2023; (32(8)):1253-1262 doi:10.1111/exd.14770.

    PMID: 36794833
  3. 3

    Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau.

    Husson B, Barbe C, Hegazy S, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2020; (34(10)):2330-2338 doi:10.1111/jdv.16265.

    PMID: 32030802
  4. 4

    Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort.

    Assan F, Husson B, Hegazy S, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2022; (36(9)):1578-1583 doi:10.1111/jdv.18127.

    PMID: 35366356
  5. 5

    [Acrodermatitis continua of Hallopeau and psoriatic arthritis: A case report].

    García C, Arellano J, Vera V, Corredoira Y

    Medwave 2020; (20(8)):e8021 doi:10.5867/medwave.2020.08.8021.

    PMID: 32956338
  6. 6

    Acrodermatitis continua of Hallopeau: clinical perspectives.

    Smith MP, Ly K, Thibodeaux Q, et al.

    Psoriasis (Auckland, N.Z.) 2019; (9()):65-72 doi:10.2147/PTT.S180608.

    PMID: 31497529
  7. 7

    Etanercept for pediatric acrodermatitis continua of Hallopeau: A case report and literature review.

    Ruggiero A, Patruno C, Napolitano M, et al.

    Dermatologic therapy 2020; (33(6)):e14046 doi:10.1111/dth.14046.

    PMID: 32700773
  8. 8

    Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature.

    Galluzzo M, D'Adamio S, Teoli M, et al.

    Dermatologic therapy 2019; (32(3)):e12899 doi:10.1111/dth.12899.

    PMID: 30969010
  9. 9

    Successful treatment of severe acrodermatitis continua of hallopeau with Bimekizumab: A case report.

    Xu L, Li K, Mutter E, Langley A

    SAGE open medical case reports 2025; (13()):2050313X241311043 doi:10.1177/2050313X241311043.

    PMID: 39850643
  10. 10

    Spesolimab in generalized pustular psoriasis complicated by acrodermatitis continua of Hallopeau: a case report and mechanistic insights.

    Hou XY, Xiao HL, Wang JY, et al.

    Frontiers in immunology 2025; (16()):1563553 doi:10.3389/fimmu.2025.1563553.

    PMID: 40443665
  11. 11

    A retrospective analysis of 65 patients with acrodermatitis continua of Hallopeau.

    Chularojanamontri L, Silpa-Archa N, Pattamadilok B, et al.

    Experimental dermatology 2024; (33(3)):e15055 doi:10.1111/exd.15055.

    PMID: 38519437
  12. 12

    Juvenile-onset pustular psoriasis: case series and literature review.

    Huang YW, Tsai TF

    The British journal of dermatology 2020; (182(3)):816-817 doi:10.1111/bjd.18473.

    PMID: 31483866
  13. 13

    Acrodermatitis continua of Hallopeau and generalised pustular psoriasis: Should they be the same or different entities?

    Chularojanamontri L, Rattanakorn K, Julanon N, et al.

    Experimental dermatology 2023; (32(8)):1235-1245 doi:10.1111/exd.14805.

    PMID: 37057764
  14. 14

    Genetic analysis of different subtypes of aseptic pustulosis in the Chinese population.

    Chen J, Xue X, Wang Z, et al.

    Clinical and experimental dermatology 2024; (49(10)):1217-1226 doi:10.1093/ced/llae144.

    PMID: 38651209
  15. 15

    [A man with a painful index finger].

    Hutting KH, Bouwer LR, Keukens FM

    Nederlands tijdschrift voor geneeskunde 2016; (160()):A9686.

    PMID: 26883842
  16. 16

    Generalized Pustular Psoriasis, Acute Generalized Exanthematous Pustulosis, and Other Pustular Reactions: A Clinical Review.

    Gössinger E, Dodiuk-Gad R, Mühleisen B, et al.

    Dermatologic clinics 2024; (42(2)):317-328 doi:10.1016/j.det.2024.01.001.

    PMID: 38423690
  17. 17

    A case of acrodermatitis continua of Hallopeau evolving into generalized pustular psoriasis successfully treated with guselkumab.

    Yamamoto H, Kamiya K, Okada H, et al.

    International journal of dermatology 2023; (62(2)):269-270 doi:10.1111/ijd.16153.

    PMID: 35187654
  18. 18

    Clinical characteristics, genetics, comorbidities and treatment of palmoplantar pustulosis: A retrospective analysis of 66 cases in a single center in Taiwan.

    Huang CM, Tsai TF

    The Journal of dermatology 2020; (47(9)):1046-1049 doi:10.1111/1346-8138.15470.

    PMID: 32613680
  19. 19

    IL36RN Mutations Affect Protein Expression and Function: A Basis for Genotype-Phenotype Correlation in Pustular Diseases.

    Tauber M, Bal E, Pei XY, et al.

    The Journal of investigative dermatology 2016; (136(9)):1811-1819 doi:10.1016/j.jid.2016.04.038.

    PMID: 27220475
  20. 20

    Coping strategies in patients with acute myeloid leukemia.

    Amonoo HL, Bodd MH, Reynolds MJ, et al.

    Blood advances 2022; (6(7)):2435-2442 doi:10.1182/bloodadvances.2021005845.

    PMID: 34768282
  21. 21

    Coping strategies and their association with diabetes specific distress, depression and diabetes self-care among people living with diabetes in Zambia.

    Hapunda G

    BMC endocrine disorders 2022; (22(1)):215 doi:10.1186/s12902-022-01131-2.

    PMID: 36031626
  22. 22

    Evaluation of the psychosocial impact and received care in patients with gestational trophoblastic disease - a qualitative interview based study.

    L J B, Y K E, S B, et al.

    Journal of psychosomatic obstetrics and gynaecology 2025; (46(1)):2451992 doi:10.1080/0167482X.2025.2451992.

    PMID: 39877952

This page provides an introductory overview of Acrodermatitis continua of Hallopeau for educational purposes only. Always consult a specialized dermatologist to confirm your diagnosis and develop a personalized treatment plan.

Get notified when new evidence is published on Acrodermatitis continua of Hallopeau.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.